Neuropathy Resource Library

Orthobiologic injections, meaning platelet-rich plasma (PRP) and bone marrow aspirate concentrate (BMAC), are offered in selected situations. No reliable ability to regenerate nerve, to reverse peripheral neuropathy, or to consistently prevent its progression has been established. That framing does not change anywhere on this page.

What can change is how much we tell you about the evidence sitting behind that framing. There is a published human literature on orthobiologics in nerve conditions. It is small, it is short, its preparations are not standardized, and much of it was built by studying people who were screened for being uncomplicated. Saying only “not approved, not established” and stopping there leaves out the part a patient with diabetes and fifteen years of burning feet most needs to hear.

So this page sets out what those studies found, who was in them, who was deliberately kept out, and what a clinician can and cannot honestly conclude from that. This is the conversation we have with patients across the St. Louis region, Missouri and Illinois before anything is injected.

Key points

• A 2024 multispecialty consensus guideline concluded that “very limited evidence” suggests perineural PRP may improve pain and numbness in diabetic peripheral neuropathy compared with conventional medical management [2].
• A systematic review of injectable biologics across neuropathic pain conditions rated the overall certainty of evidence as very low by GRADE criteria [3].
• Every human study of PRP in diabetic peripheral neuropathy that we located added PRP to medical management. None tested it as a stand-alone treatment [4][5].
• These trials routinely exclude diabetes, systemic disease, severe disease and overlapping neuropathies — much of the patient profile this practice actually treats [8][9][10].
• Peripheral neuropathy covers at least seven distinct pathophysiologic phenotypes [1]. The driver decides what belongs in a plan.
• Untested is not the same as promising. Both sentences get said here, with the same weight.

First, the condition is not one thing

Burning, numbness and electric sensations are the alarm. They are not the wiring fault. A 2026 phenotype-driven review classifies peripheral neuropathy into distal “dying-back” axonopathy, neuronopathy (ganglionopathy), demyelinating neuropathies, small-fiber neuropathy, autonomic neuropathy, ischemic, infiltrative or inflammatory axonopathies, and focal compressive or entrapment neuropathies [1].

Seven mechanisms, one symptom vocabulary. That is why a general claim about “injections for neuropathy” is not a claim about anything in particular, and it is also why the studies below cannot simply be added together. A trial in carpal tunnel syndrome and a trial in diabetic polyneuropathy are not studying the same disease.

What orthobiologic injections are

PRP is the patient’s own blood, drawn and centrifuged to concentrate platelets and the growth factors they carry. BMAC is bone marrow aspirated from the patient, then centrifuged to concentrate the mononuclear cell fraction, which includes mesenchymal cells that have not been culture-expanded.

The 2024 consensus guideline describes these as the pillars of regenerative medicine in pain practice and notes the regulatory frame they sit in: under Section 361 of the Public Health Service Act and the associated federal regulations, only minimally manipulated products in homologous use are permitted, nothing may be added to the product, and it should not have a systemic effect. Culture-expanding cells is more than minimal manipulation and is not permitted on that pathway [2].

That matters for reading claims. A regulatory pathway that allows a same-day autologous product is not a finding that the product works. Those two things are easy to blur and are routinely blurred in advertising.

What the published evidence actually shows

The formal guideline position

A multispecialty working group published evidence-based clinical practice guidelines on regenerative medicine for chronic pain in 2024. Its Consensus Point 27 states that very limited evidence suggests perineural injection of PRP along certain nerves, including the median, ulnar, radial, peroneal, tibial, saphenous and sural nerves, may be associated with improvements in pain intensity and neurological symptoms such as numbness in patients with diabetic peripheral neuropathy, compared with conventional medical management [2].

That is the strongest formal statement in this field, and it is deliberately hedged. The same guideline reports that a systematic review of 27 human studies of injectable biologics for neuropathic pain — covering post-spinal-cord-injury pain, diabetic peripheral neuropathy, painful scars, pudendal neuralgia, trigeminal neuralgia, carpal tunnel syndrome, peripheral neuropathy and radiculopathy — found very low certainty of evidence by GRADE criteria [2][3]. The review’s authors called for standardized preparation, dosage and route before higher-quality trials could be run [3].

Diabetic peripheral neuropathy: two small studies, both combination designs

The first is a randomized trial of 60 adults with type 2 diabetes and diabetic peripheral neuropathy of at least six months’ duration, conducted at a university hospital pain clinic and rheumatology and rehabilitation departments in Egypt. One group received ultrasound-guided perineural PRP plus medical treatment; the other received medical treatment alone. Patients were followed at one, three and six months. Pain and numbness visual analog scores and the modified Toronto Clinical Neuropathy Score improved in the PRP group compared with the control group at every time point [4].

The honest reading: 60 people, one center, six months, and the comparison was PRP-plus-medication against medication alone, not PRP against a sham injection. The full text sits behind a subscription and we could not verify its exclusion criteria; the published abstract does not state them, and we are not going to guess at them.

The second is a prospective case-control study of 80 people with type 2 diabetic peripheral neuropathy, 40 receiving ultrasound-guided perineural PRP with medical treatment and 40 receiving medical treatment alone. In the intervention group, tibial motor nerve conduction velocity rose from 38.5 ± 5.2 to 45.3 ± 4.8 m/s and peroneal motor conduction from 36.2 ± 4.9 to 42.7 ± 5.1 m/s at three months. The modified Toronto score fell from 12.4 ± 2.1 to 6.3 ± 1.8 and pain from 8.2 ± 1.0 to 3.5 ± 1.2. The control group worsened on both scores over the same period [5].

The honest reading: this was a case-control design, not a randomized one. Participants were not assigned by chance, so a difference between the groups that nobody measured can produce a result like this. Follow-up was three months. This paper is also behind a subscription and its exclusion criteria could not be verified.

Those two studies, roughly 140 people between them at two centers over three to six months, are the clinical evidence base for PRP in diabetic peripheral neuropathy that we were able to locate. That is not a reason to dismiss them. It is a reason not to build a promise on them.

Bone marrow cells: studied, but not as BMAC and not around the nerve

A 2024 systematic review and meta-analysis screened 5,431 records and found seven controlled trials of stem cell therapy in diabetic peripheral neuropathy, covering 400 patients with a mean age of 62.4 ± 8.5 years. Six were conducted in China in people with type 2 diabetes; one in Egypt included both type 1 and type 2. Five used bone marrow-derived mononuclear cells and two used umbilical cord-derived mesenchymal stromal cells. All but one delivered the cells by intramuscular injection into the leg; the remaining study used intravenous delivery [6].

Pooled results favored treatment: motor nerve conduction velocity improved by 2.2 m/s (95% CI 1.6 to 2.8), sensory conduction by 1.9 m/s (95% CI 1.1 to 2.6), vibration perception threshold fell by 2.9 V (95% CI −4.0 to −1.8) and the Toronto Clinical Scoring System fell by 3.6 points (95% CI −5.0 to −2.2). Reported complications were pain and swelling at the injection sites, resolving within days [6].

The honest reading, in the review authors’ own terms: only one of the seven trials was randomized, four of the seven raised risk-of-bias concerns, follow-up ran only to 3, 6 or 12 months, and the field lacks high-quality controlled trials with large sample sizes and any long-term safety follow-up [6].

There is also a design point that matters directly to a patient asking about an injection. Those cells went into leg muscle, not around a nerve. Bone marrow-derived mononuclear cells are a close relative of BMAC, which is bone marrow aspirate centrifuged to concentrate that same cell fraction [2], but the preparations are not standardized across studies and neither is the route. This evidence does not transfer cleanly to a perineural BMAC injection, and we do not present it as though it does. A 2026 review of orthobiologics in type 2 diabetes states that evidence for BMAC and mesenchymal stromal cell outcomes specifically in diabetic patients remains sparse [11].

Entrapment neuropathy: the best-studied nerve indication, and where its ceiling shows

Carpal tunnel syndrome is a focal compressive neuropathy, and it has more PRP data than any other nerve condition. A 2025 meta-analysis pooled seven randomized trials covering 365 patients, 183 receiving PRP and 182 receiving conventional non-surgical care, all with mild to moderate disease [7].

Symptom severity improved with PRP at one, three and six months and functional status at three and six months. Pain scores were lower at three months but not at one. Meanwhile the cross-sectional area of the median nerve, sensory nerve conduction velocity and distal motor latency showed no statistically significant difference between groups at any time point. No serious adverse reactions were recorded in the four studies that tracked them [7].

Both halves of that are true at once. In the nerve condition with the most PRP evidence, what improved was how people felt and functioned; the electrical and ultrasound measurements of the nerve did not follow. Neither half should be dropped when the result is quoted.

A 2025 randomized controlled trial adds a harder finding. Seventy-five patients with mild to moderate idiopathic carpal tunnel syndrome were assigned in equal groups to perineural bupivacaine with methylprednisolone, to pulsed radiofrequency with bupivacaine, or to perineural PRP. All three groups improved in pain, symptoms, function, median nerve cross-sectional area and nerve conduction. Pulsed radiofrequency and steroid produced greater improvement than PRP, and the PRP group showed the least improvement of the three over the four-month study [8].

That is a modest-to-negative result for PRP and we are not going to soften it. What we will do is say who was in that trial, because it changes what the result can be used to conclude.

Other nerve conditions: small, and mostly uncontrolled

An open-label interventional study gave a single 1 mL perineural PRP injection to 30 patients with Hansen’s disease and ulnar or common peroneal neuropathy; 27 completed 12 weeks of follow-up. Two-point discrimination, area of sensory loss, hand dynamometry and foot muscle power improved, activity-limitation scores improved at 12 weeks, and motor nerve conduction amplitude rose while sensory latency fell and sensory conduction velocity rose at 12 weeks. No adverse effects were recorded beyond one to two days of injection-site pain [9].

There was no control group. In a single-arm open-label study over 12 weeks, in patients who were also on multidrug therapy for the underlying infection, treatment effect cannot be separated from natural recovery or expectation. The authors say as much, and note that long-term effects could not be assessed.

A single-blind randomized comparative trial studied 30 men with incomplete traumatic sciatic nerve injury, assigning them to five weekly ultrasound-guided 5 mL perineural PRP injections plus 12 weeks of rehabilitation, or to rehabilitation alone, with six months of follow-up. At one month, PRP had not improved the motor or sensory function scales. By three and six months, motor function ratings and conduction velocities favored the PRP group over rehabilitation alone. The authors’ own conclusion is that PRP “may be partially effective” in the early repair of incomplete sciatic nerve injuries [10].

Why these studies do not answer the question a complex patient is asking

The people who were screened out

This is the part that decides how much weight any of the above can carry, and it is checkable in the papers themselves.

The carpal tunnel trial in which PRP performed worst excluded, in the authors’ words, “secondary CTS due to systemic disease including thyroid disease, diabetes mellitus, or acromegaly.” It also excluded severe carpal tunnel syndrome, defined as distal motor latency to abductor pollicis brevis above 6.5 ms or absent median sensory potentials or a nerve cross-sectional area above 15.0 mm², along with “other neuropathies overlapping with CTS,” previous median nerve release or wrist surgery, pregnancy, concurrent steroids, known allergy to the study medications, and any carpal tunnel injection in the previous six months. Enrollment was restricted to ages 20 to 60 with mild to moderate idiopathic disease that had already failed at least three months of conservative care [8].

The sciatic nerve trial enrolled only men aged 18 to 60 with an incomplete injury three weeks old who had received no other treatment. The authors state that “patients without other diseases were included,” and excluded pre-existing bilateral sciatic dysfunction and severe cardiopulmonary, hematological, skin, infectious, oncological and psychiatric disorders [10].

The Hansen’s disease study excluded uncontrolled diabetes mellitus, known severe cardiac, hepatic or renal disease, antiplatelet medication, non-steroidal anti-inflammatory drugs within a week, systemic steroids above 20 mg daily, local steroid injection within six months, disease diagnosed more than three years earlier, active lepra reactions, and anyone with a platelet count below 50 × 10³, hemoglobin below 10 g/dL or mean platelet volume above 12.3 fL [9].

The carpal tunnel meta-analysis pooled only mild to moderate disease treated non-surgically. Severe disease was not in the pool, and surgical patients were excluded by design [7].

Now read that list against the person who usually walks into this clinic: type 2 diabetes or insulin resistance, often obesity, frequently on an antiplatelet agent, ten or twenty years of symptoms, more than one driver at once, and several treatments already tried without success. Most of them would not have been enrolled in most of these studies.

Two conclusions follow, and they point in opposite directions. Both are true and we state both.

First, a modest or negative result in a screened, uncomplicated population does not establish that a treatment fails in the patients who were screened out. That is the ordinary external-validity problem, and it is why we do not treat the carpal tunnel finding as a verdict on orthobiologics in metabolic neuropathy.

Second, and just as important, it means there is no evidence that these injections help those patients either. Untested is not the same as promising. Anyone who uses the first conclusion without the second is selling something.

What a short single-modality study cannot measure

Every diabetic neuropathy study we located tested PRP added to medical management [4][5]. None isolated PRP against a sham, and none tested it inside a sequenced plan that also corrects perfusion, glycemic control and the substrates repair requires. A study of one modality cannot report on a combination it never assembled.

Follow-up across this entire literature ran from three to twelve months [6][7][8][9][10]. Nothing here speaks to what happens after a year, and peripheral neuropathy is measured in decades.

Outcome measures also disagree with each other. In carpal tunnel, symptoms and function moved while nerve conduction and nerve size did not [7]. In diabetic neuropathy, conduction velocities moved [5]. Those are different questions, they can genuinely diverge, and a study that measures one is silent about the other. Function — walking, balance, sleeping through the night — is often not measured at all.

Efficacy under trial conditions is also a different question from effectiveness in practice. Preparation protocols, platelet doses, leukocyte content, injection volumes, nerve targets and number of sessions were not standardized across these studies, which is precisely what the 2022 systematic review asked the field to fix before running larger trials [3].

Metabolic dysfunction may change the biologic itself

There is a complication in this literature that nobody advertises, and it deserves stating plainly because it cuts against easy optimism.

A 2026 narrative review of orthobiologic therapy in type 2 diabetes reports that people with type 2 diabetes show reduced responsiveness to PRP, BMAC and mesenchymal stromal cell preparations. It attributes this to advanced glycation end-product accumulation, NF-κB-driven chronic inflammation, impaired Nrf2 antioxidant signaling, mitochondrial dysfunction and persistent epigenetic changes it calls “diabetic memory.” It summarizes published reports that PRP from diabetic donors can carry higher VEGF concentrations and still produce inferior clinical results, and that bone marrow mobilization failure has been documented at 15.6% in diabetic patients compared with 6.4% in non-diabetic controls. The review states that its own framework is hypothesis-generating rather than a clinical protocol [11].

That is a caution, not a selling point. If metabolic terrain is the rate-limiting step, then treating the terrain is the treatment, and anything injected into unchanged terrain is being asked to do a job the surrounding tissue cannot support. It is one of the reasons metabolic and nutritional care is the foundation here rather than an add-on to a procedure.

How evidence strength varies across other options

It helps to see what a stronger evidence base looks like in the same condition. For painful diabetic peripheral neuropathy, adding 10 kHz spinal cord stimulation to optimized medical management produced markedly higher responder rates at six months in a randomized trial, with benefit sustained through 24 months [1]. Ultrasound-guided pulsed radiofrequency for focal entrapment-type neuropathic pain sits differently: reported benefits are generally short to mid-term with heterogeneous protocols, so certainty varies by indication [1].

The 2026 review that describes both of those describes itself as a narrative review, not a formal practice guideline [1]. “Described in the literature” and “standard of care” remain different statements. Apply the same structure to orthobiologics: ask about the specific phenotype and the specific indication, not about “neuropathy” in general.

What is still not established

• No reliable ability to regenerate nerve, reverse peripheral neuropathy, or consistently prevent its progression has been established for orthobiologic injections in any neuropathy type.
• They are not FDA-approved for this indication. Autologous PRP and same-day BMAC are used under minimal-manipulation, homologous-use provisions [2], which is a regulatory pathway and not a finding of efficacy.
• We located no head-to-head trial comparing PRP with BMAC in any peripheral neuropathy.
• We located no study testing orthobiologics in a length-dependent polyneuropathy alongside photobiomodulation and metabolic correction, which is the only way the question would ever arise here.
• Insurance coverage is a payer decision, not a clinical finding. Patients sign an advance beneficiary notice for non-covered services. Whether something is covered says nothing about whether it works.

What would actually settle the question

A patient is entitled to know what a real answer would require. It would take the following, and none of it exists yet.

1. A randomized trial with a credible sham injection, rather than a medication-only comparison group.
2. Enrollment that deliberately includes metabolic dysfunction, obesity, long symptom duration, polypharmacy and prior failed treatment, with analysis planned in advance for those subgroups instead of excluding them.
3. A standardized and fully reported preparation: platelet dose, leukocyte content, volume, nerve target and number of sessions [3].
4. Outcomes covering both what patients feel and what can be measured, since symptom scores and nerve conduction have already been shown to move independently of each other [5][7].
5. Follow-up well beyond twelve months, which nothing in the current literature provides [6].
6. Trials that test the injection inside a combination protocol, because a combination is the only setting in which it would be used.

What we do instead of guessing

Map the driver before choosing a therapy

Metabolic, nutritional, autoimmune, toxic and structural drivers overlap and frequently coexist. Identifying the dominant one changes what belongs in the plan more than any single modality does.

The reasoning behind that approach is set out in the science of nerve terrain rehabilitation.

Test to answer a question

We perform electrodiagnostic testing (EMG/NCS) on site. It characterizes large-fiber involvement and localizes a problem, and it can be normal in small fiber neuropathy, so a normal study does not end the evaluation.

Videonystagmography (VNG) is used as a diagnostic test of inner-ear balance function when unsteadiness is part of the picture. It is not a treatment for neuropathy or for anything else.

Treat the terrain the nerve depends on

Restoring perfusion so oxygen reaches the nerve, reducing the metabolic pathways that keep producing glycation injury, and supplying the substrates repair requires are the foundation. Class 4 photobiomodulation, class 3B cold laser and whole-body infrared are used as part of that, matched to the clinical picture.

Qutenza (capsaicin 8% patch) is FDA-approved in adults for neuropathic pain from postherpetic neuralgia and from diabetic peripheral neuropathy of the feet. Use for any other driver is off-label. It is applied in clinic by a clinician, never dispensed for home use, and repeated no more often than every three months.

How risk and benefit get discussed

We do not promise nerve regeneration or reversal of established nerve damage.

We state what is known about safety separately from what is known about benefit. Across this literature the reported adverse effects were injection-site pain, swelling and bruising resolving within days [6][7][9][10], and the 2024 consensus panel described PRP and mesenchymal cell products as having minimal injection-related adverse effects with rare severe reactions [2]. Safety is not efficacy. A treatment can be safe and still not help.

We do not offer an injection in place of finishing a workup, and we do not offer one to a patient whose dominant driver has not been identified. Where a service is not covered, that is discussed as a payer decision and documented before anything happens, not presented as a comment on whether the treatment works.

“My ethos is to treat all of my patients as I would my own family, with the goal of giving them back their quality of life.” — Dr. Gurpreet Singh Padda, MD, MBA, MHP

Questions worth bringing to the visit

1. Which neuropathy phenotype do you think I have, and what supports that?
2. Which driver is dominant in my case, and how did you establish it?
3. Which parts of this plan are established, and which are less certain?
4. If you are recommending an injection, which study are you relying on, and were patients like me eligible for it?
5. What are we doing about the metabolic terrain, and in what order relative to any procedure?
6. How will progress be measured, and over what period?
7. Do my test results and my symptoms actually agree? If not, what explains the gap?

A clinician who cannot answer the third and fourth questions in plain language is the reason to slow down.

For context on what is used here: Regenerve prepares platelet-rich plasma leukocyte-poor — no white cells, no red cells — activated with calcium chloride, at two to three times baseline platelet concentration with higher dosing in the six to twelve times range, targeting a measured dose above ten billion platelets per joint.

Frequently asked questions

Are PRP or BMAC injections approved for peripheral neuropathy?

Orthobiologic injections are offered in selected situations. Autologous PRP and same-day BMAC are used under federal minimal-manipulation rules, which is a regulatory pathway rather than a finding that they work. See the Regenerve Protocol for peripheral neuropathy.

Is there any published research on PRP for diabetic neuropathy?

Yes, but very little. A randomized trial of 60 people and a non-randomized case-control study of 80 people both reported improvement when PRP was added to medical treatment, over three to six months, and a 2024 consensus guideline calls that “very limited evidence.” Neither study tested PRP on its own against a sham injection. See diabetic peripheral neuropathy treatment in St. Louis.

Why do you say trials may not apply to me?

Because these studies routinely screen out the people this clinic treats. One carpal tunnel trial excluded diabetes, thyroid disease, severe disease and any overlapping neuropathy; a sciatic nerve trial enrolled only men aged 18 to 60 with no other diseases. That means a weak result in those groups does not prove failure in complex patients, and it also means nobody has shown benefit in them. See the hidden drivers of peripheral neuropathy.

Can an EMG and nerve conduction study confirm small fiber neuropathy?

Not on its own. Nerve conduction studies assess large-fiber function and can be normal in small fiber neuropathy, so a normal result does not close the question. The symptom pattern still has to be matched to the right test. See small fiber neuropathy symptoms and testing.

Does VNG balance testing treat neuropathy?

No. Videonystagmography is a diagnostic test of inner-ear balance function, used to tell a vestibular contribution apart from a nerve contribution when someone is unsteady. It treats nothing. See VNG balance testing.

Next step

Before any injection question is worth asking, the driver has to be identified. Five questions start that map, and it takes a couple of minutes.

Sources

1. Yuba T, Dabbagh A, Sabouri AS. Peripheral neuropathy: a phenotype-driven review for diagnosis and management. Rev Neurol. 2026;81(4):48384. doi:10.31083/RN48384. PMID 42052783. https://pmc.ncbi.nlm.nih.gov/articles/PMC13129557/
2. D’Souza RS, Her YF, Hussain N, et al. Evidence-based clinical practice guidelines on regenerative medicine treatment for chronic pain: a consensus report from a multispecialty working group. J Pain Res. 2024;17:2951-3001. doi:10.2147/JPR.S480559. PMID 39282657. https://pmc.ncbi.nlm.nih.gov/articles/PMC11402349/
3. Bies M, Ashmore Z, Qu W, Hunt C. Injectable biologics for neuropathic pain: a systematic review. Pain Med. 2022;23(10):1733-1749. doi:10.1093/pm/pnac066. PMID 35482528. https://pubmed.ncbi.nlm.nih.gov/35482528/
4. Hassanien M, Elawamy A, Kamel EZ, et al. Perineural platelet-rich plasma for diabetic neuropathic pain, could it make a difference? Pain Med. 2020;21(4):757-765. doi:10.1093/pm/pnz140. PMID 31298289. https://pubmed.ncbi.nlm.nih.gov/31298289/
5. Elsayed AA, Eldeen ES, Osman MA, Elazab SA. Role of platelet rich plasma in management of diabetic peripheral neuropathy: a case-control study. J Ultrasound. 2025. doi:10.1007/s40477-025-01042-7. PMID 40624430. https://pubmed.ncbi.nlm.nih.gov/40624430/
6. Alizadeh SD, Jahani S, Rukerd MRZ, et al. Human studies of the efficacy and safety of stem cells in the treatment of diabetic peripheral neuropathy: a systematic review and meta-analysis. Stem Cell Res Ther. 2024;15(1):442. doi:10.1186/s13287-024-04033-3. PMID 39563393. https://pmc.ncbi.nlm.nih.gov/articles/PMC11577959/
7. Du Y, Jiang X, Fu K, Cui C. Efficacy and safety of platelet-rich plasma in the treatment of carpal tunnel syndrome: a meta-analysis. Medicine (Baltimore). 2025;104(44):e45010. doi:10.1097/MD.0000000000045010. PMID 41261653. https://pmc.ncbi.nlm.nih.gov/articles/PMC12582690/
8. Hashem EY, Shamandy FS, Elmulla AF, Mansour MA. Ultrasound-guided pulsed radiofrequency versus perineural platelet rich plasma injection for the treatment of idiopathic carpal tunnel syndrome: a prospective randomized controlled study. BMC Anesthesiol. 2025;25(1):406. doi:10.1186/s12871-025-03257-x. PMID 40804365. https://pmc.ncbi.nlm.nih.gov/articles/PMC12351916/
9. Saha A, Kothari SY, Sonune S, et al. Effect of single perineural injection of platelet rich plasma on nerve function in Hansen’s disease with truncal neuropathy: an interventional study. Cureus. 2026;18(1):e102127. doi:10.7759/cureus.102127. PMID 41732637. https://pmc.ncbi.nlm.nih.gov/articles/PMC12925252/
10. Yang C, Wang C, Wang C, Yang G, Wu W. The effectiveness of platelet-rich plasma in the treatment of sciatic nerve injury: a single-blind randomized comparative trial. Neural Plast. 2025;2025:7540054. doi:10.1155/np/7540054. PMID 41306443. https://pmc.ncbi.nlm.nih.gov/articles/PMC12646722/
11. Santos MDS, Costa FR, Protasio Netto J, et al. Nutritional interventions to optimize orthobiologic therapy quality in type 2 diabetes mellitus: molecular mechanisms and clinical framework: a narrative review. Int J Mol Sci. 2026;27(9):3749. doi:10.3390/ijms27093749. PMID 42123336. https://pmc.ncbi.nlm.nih.gov/articles/PMC13164227/

Get numbness in your feet evaluated promptly when it comes on suddenly, when it is much worse on one side, when it comes with real weakness, when there are autonomic changes such as lightheadedness on standing, or when it is progressing over days to weeks. American Family Physician names those same features as the reasons to refer a patient for electrodiagnostic studies, along with an initial workup that is normal while symptoms continue.¹ Slow, symmetrical numbness in both feet is less urgent, but it still deserves a workup, because it is usually reporting a driver somewhere else in the body.

What to notice before your visit

• Numbness that is spreading or getting worse. A changing pattern suggests the driver is still active.
• Numbness plus weakness or autonomic changes. These are the features that move evaluation forward in the queue.
• A diabetes or prediabetes history. Peripheral neuropathy affects 25% to 50% of patients with diabetes, depending on age, years with diabetes, and control.¹
• Known abnormal labs. B12, thyroid, and metabolic results shape which driver is most likely.
• Burning, heat, and night symptoms. Small-fiber patterns can be intense while standard testing looks unremarkable.
• Balance changes. Reduced protective sensation makes missteps more likely.

When numbness in the feet becomes urgent, and why

Numbness means nerve signaling is impaired. When the impairment progresses, it stops being only a sensation problem and becomes a safety problem — walking, heat sensitivity, and balance all depend on that feedback.

Worrisome patterns that support earlier evaluation

American Family Physician advises referral for electrodiagnostic studies when symptoms are worrisome, giving acute onset, asymmetry, predominantly motor or autonomic symptoms, and a rapidly progressive course as the examples, or when the initial workup is normal and symptoms persist.¹

• Sudden or rapidly developing numbness
• Clear asymmetry, much more on one side than the other
• Prominent weakness rather than numbness alone
• Autonomic features such as lightheadedness on standing or changed sweating
• Progression over days to weeks

Numbness without pain still deserves evaluation

An epidemiological survey of 5,682 Japanese respondents, published in 2023, examined numbness that is not accompanied by pain, using the EQ-5D-3L and found that quality of life fell as numbness intensity rose.² Notably, in that survey numbness of the feet and numbness in younger respondents were less likely to affect quality of life than numbness elsewhere.

That nuance is worth stating plainly: the absence of pain, and even a modest quality-of-life impact, is not evidence that the nerve is uninjured. It only means the symptom is quiet.

How common is peripheral neuropathy?

American Family Physician reports that the prevalence of peripheral neuropathy in the general population ranges from 1% to 7%, with higher rates among those older than 50 years.¹ The range is wide, but the direction is consistent, and age raises the risk.

When the cause is not obvious

The same source notes that peripheral neuropathy is idiopathic in 25% to 46% of cases, and that this becomes more common with increasing age.¹ A clean explanation may not appear at the first visit, which is what makes a structured evaluation worth the effort rather than a formality.

The diabetes context

Peripheral neuropathy affects 25% to 50% of patients with diabetes, depending on age, number of years with diabetes, and level of control.¹ If diabetes is part of your history, numbness in the feet is a planning decision rather than a wait-and-see symptom, because metabolic drivers tend to progress quietly.

What we are actually mapping

Neuropathy is a category, not a diagnosis. The driver decides the direction of treatment, so the evaluation is built to name it rather than to confirm a label. Several of the drivers that get missed on a first pass are covered in our review of the hidden drivers behind peripheral neuropathy.

The questions that organize the map

• Is the pattern length-dependent, starting in the toes and moving up?
• Are the symptoms mostly positive, such as burning and tingling, or mostly negative, such as reduced sensation?
• Does the picture fit small-fiber involvement, with burning and altered temperature sensation?
• Is there metabolic risk that points toward a diabetic or prediabetic driver?
• Is there a nutritional, medication, or toxic exposure history that points somewhere else?

Testing that clarifies the driver rather than the label

Evaluation is decision-making. We want to know which nerves are involved, what is damaging them, and whether the mechanism looks metabolic, nutritional, toxic, autoimmune, or structural.

Initial laboratory evaluation

American Family Physician describes initial testing that includes a complete blood count, a comprehensive metabolic profile, and fasting blood glucose, thyroid-stimulating hormone, and vitamin B12 levels.¹ Those results are read in context with the symptom pattern, never in isolation.

Electrodiagnostic testing: what it can and cannot do

Electrodiagnostic studies measure how well the larger nerve fibers conduct. They do not replace symptom-pattern analysis, and they cannot see the smallest fibers, but they can separate a normal-looking report from a measurable conduction failure. Electrodiagnostic testing (EMG/NCS) is performed on site at Regenerve.

Why burning feet at night can still matter when testing looks normal

Small-fiber symptoms often arrive first in metabolic neuropathy, including burning and altered temperature sensation. That is the situation people find most confusing, because the report can look unremarkable while the sensation is severe.

VNG balance testing when numbness comes with dizziness

VNG (videonystagmography) is a diagnostic test of inner-ear balance function, not a treatment. When numbness comes with dizziness or unsteadiness, it helps separate an inner-ear contribution from a nerve contribution so the plan targets the right system.

Why cause-first planning changes what you do next

The feet report first because the longest nerves carry the highest demands and depend on the longest supply route for oxygen and nutrients. When that supply is compromised, those fibers misfire first.

Diabetic peripheral neuropathy behaves as a microvascular and metabolic problem that happens to appear in the feet, which is why treatment aimed only at the sensation tends to leave the driver untouched.

What is offered here, described accurately

Class 4 photobiomodulation, class 3B cold laser, and whole-body infrared are offered in clinic alongside metabolic and nutritional care, guided by what the evaluation finds. Orthobiologic injections (PRP and BMAC) are offered as well. We do not promise nerve regeneration, reversal, or a cure, and we publish no success rate for any of it.

What you can do before your visit

• Inspect your feet daily with a mirror if protective sensation is reduced, so skin breakdown is found early.
• Write down the timing and progression, including whether burning is worse at night and whether symptoms are spreading.
• Note exposures, medications, and metabolic history, including diabetes status, nutrition, and any chemotherapy.

Where we are and how to start

Regenerve is located at 4477 Woodson Rd #104, St. Louis, MO 63134, minutes from St. Louis Lambert International Airport, and we see patients from across the St. Louis region, Missouri and Illinois. You can call or text (314) 886-5902, or email info@regenerve.com.

The free Nerve Damage Score is a five-question starting point that organizes the driver question before your appointment. If your numbness is new, worsening, or paired with any of the red flags above, do not wait on it.

Frequently asked questions

How do I know whether numbness in my feet is urgent?

Treat it as urgent when the onset is sudden, the numbness is clearly worse on one side, there is real weakness rather than only numbness, there are autonomic features such as lightheadedness on standing, or the change is progressing over days to weeks. American Family Physician lists exactly those features as reasons to refer for electrodiagnostic studies.¹ See the symptom patterns we look for in the feet.

Do I need an EMG or nerve conduction study if I only have numbness?

Not always. Electrodiagnostic testing earns its place when the symptoms are worrisome, or when the initial workup is normal and the symptoms persist. That testing is performed on site here, so the decision is about whether the result will change the plan. See which specialist to see when neuropathy has not improved.

What laboratory tests are usually part of the first workup?

American Family Physician describes initial testing that includes a complete blood count, a comprehensive metabolic profile, and fasting blood glucose, thyroid-stimulating hormone, and vitamin B12 levels.¹ Those results point toward a metabolic, nutritional, or thyroid driver rather than confirming a label. See why a “normal” B12 result can still be misleading.

Can burning feet at night be small fiber neuropathy?

It can. Burning and altered temperature sensation often appear early in metabolic neuropathy, and standard nerve conduction studies can look unremarkable while symptoms are intense, because those studies do not measure the smallest fibers. See small fiber neuropathy symptoms and testing.

Where does Qutenza fit into treating numb or burning feet?

Qutenza (capsaicin 8% patch) is FDA-approved in adults only for neuropathic pain from postherpetic neuralgia and from diabetic peripheral neuropathy of the feet. Any other neuropathy driver would be off-label use. It is applied in clinic by a clinician, never dispensed for home use, and repeated no more often than every three months. See how Qutenza is used in clinic.

Sources

1. Castelli G, Desai KM, Cantone RE. Peripheral Neuropathy: Evaluation and Differential Diagnosis. American Family Physician. 2020;102(12):732-739. https://www.aafp.org/pubs/afp/issues/2020/1215/p732.html (general-population prevalence of 1% to 7%; idiopathic in 25% to 46% of cases; 25% to 50% of patients with diabetes; initial laboratory evaluation; criteria for electrodiagnostic referral).
2. Nagai S, Niwa H, Terajima Y, et al. The Relationship between Numbness and Quality of Life. Journal of Clinical Medicine. 2023;12(4):1324. https://doi.org/10.3390/jcm12041324 (epidemiological survey of 5,682 Japanese respondents; quality of life declined as the intensity of numbness without pain increased, with foot numbness and numbness in younger respondents less likely to affect quality of life).

If neuropathy is making you unsteady, the useful next step is to identify which driver is damaging your nerves — metabolic, nutritional, autoimmune, toxic, or structural — and then match testing and rehabilitation to that driver. Balance depends on accurate sensation coming back from your feet, and when that signal is degraded, ordinary walking becomes harder to control. Mapping the driver first is what keeps a falls-prevention plan from turning into guesswork.

Falls are the leading cause of injury for adults ages 65 years and older in the United States, and more than 14 million of those older adults, about 1 in 4, report falling every year.¹ Neuropathy is one of the reasons that number stays high.

What we look at first

• Which driver is active. Different drivers create different failure patterns, so the plan changes with the mechanism.
• Metabolic and microvascular strain. When oxygen delivery to the small vessels supplying a nerve is reduced, signaling becomes less reliable.
• Nutritional contributors. Vitamin-related drivers, including B12, can affect both sensation and coordination.
• Toxic and environmental exposures. Heavy metals and other exposures can injure nerves independently of blood sugar.
• Objective testing rather than assumption. Electrodiagnostic testing (EMG/NCS) is performed on site and can clarify the nerve pattern.
• Function, not just pain. Steadiness while walking, turning, and stepping down is the outcome that matters for falls.

Why neuropathy affects balance in the first place

Balance uses several systems at once: sensation from the feet, motor control, vision, and inner-ear signaling. When peripheral neuropathy blunts sensory feedback, the brain loses part of its information about how the foot is meeting the ground.

Many neuropathy drivers also injure the fibers that help with timing. That is why unsteadiness in neuropathy is usually not simple weakness — it is the nervous system misreading the ground in real time.

The wiring problem behind numbness and unsteady stepping

Medication that quiets the signal does not repair the wiring. The alarm keeps ringing because the underlying problem is still running, and walking is the moment in the day when that error shows itself.

This is especially true in diabetic peripheral neuropathy, which behaves as a microvascular and metabolic problem that happens to show up in the feet. When perfusion is reduced, nerves work with less oxygen and send less reliable signals.

When reduced sensation becomes a falls trigger

If protective sensation is reduced, a foot can feel unremarkable while pressure, temperature, and position information are all degraded. That mismatch is what turns a small stumble into a fall.

So the goal of treating numbness is not only less burning. It is more accurate information reaching the brain while you walk.

The drivers we map before we plan anything

Neuropathy is a category, not a diagnosis. Naming the specific driver is what decides which tests are worth doing and what treatment should target.

Diabetic and metabolic drivers

Diabetic neuropathy is rarely a feet-only problem. It usually combines reduced microvascular perfusion with metabolic pathway damage that affects both nerve function and the coordination of stepping.

A systematic review and meta-analysis published in 2025, pooling 32 studies covering 23,666 older adults with diabetes, found a falls prevalence of 29.5% in that population.² That is the group in which a balance conversation should start early rather than after an injury.

Nutritional drivers, including B12

Vitamin B12 deficiency can affect both sensation and coordination, and it can make burning or numbness worse. When a nutritional driver is present, unsteadiness can progress faster than the pain does.

That is why diet pattern, digestion, and laboratory context belong in the evaluation. Treating the symptom while the driver keeps running does not change the trajectory.

Autoimmune, toxic, and treatment-related contributors

Immune-mediated processes can make nerve signaling more erratic, which shows up when you change pace, step off a curb, or turn quickly. Chemotherapy is a well-recognized cause of nerve injury that produces both sensory loss and timing problems.

Toxic and environmental exposures can damage nerves and small vessels as well. When exposure history fits, that belongs in the driver map alongside everything else. Several of these mechanisms are covered in our review of the neuropathy drivers that are most often missed.

When the label says idiopathic

“Idiopathic” does not mean no cause. It often means the evaluation did not find the active one, and mixed presentations are common — metabolic plus nutritional, or autoimmune plus structural.

If you have been told there is nothing to be done about the cause, that is a reason to re-check the driver map, not a reason to stop.

What evaluation looks for when falls are the concern

When someone comes in worried about falling, the first question is not which medication they are taking. It is which driver is active, and what functional failure it is producing.

On-site electrodiagnostic testing

Electrodiagnostic testing (EMG/NCS) is performed on site at Regenerve and can help clarify which nerves are involved and what pattern is present. Those findings guide decisions instead of leaving the plan to symptom description alone.

VNG balance testing is diagnostic, not a treatment

VNG (videonystagmography) evaluates inner-ear balance function. It is a diagnostic test, never a treatment, and its value here is separating an inner-ear contribution from a peripheral nerve contribution.

When unsteadiness has more than one contributor, which is common in older adults, that separation is what keeps the plan from targeting the wrong system.

Small-fiber and autonomic contributors

Small fiber involvement can produce burning and hot-coal sensations, and it can also affect autonomic function. When autonomic signaling is involved, blood pressure regulation can shift, which changes real-world steadiness during standing and turning.

How treatment and rehabilitation fit together

Treatment has to do two things at once. It has to reduce the injury still being done to the nerve, and it has to support the function that keeps you upright.

In-clinic modalities

Class 4 photobiomodulation, class 3B cold laser, and whole-body infrared are offered in clinic as part of a broader, driver-based plan. We do not present them as nerve regeneration, reversal, or a cure, and we do not publish a success rate for them.

Orthobiologic injections and the honest framing

Orthobiologic injections (PRP and BMAC) are offered here. Nothing about them should be described as a repair of nerve injury.

Metabolic and nutritional care matched to the driver

Metabolic and nutritional care is built around whichever driver is active, which is why the same symptom can lead to two different plans. The point is to stop the ongoing injury while function is worked on.

Daily habits that lower falls risk when sensation is reduced

• Remove trip hazards and keep lighting consistent, especially on the route you walk at night.
• Wear supportive footwear and avoid walking barefoot when protective sensation is reduced.
• Slow your turns and transitions, particularly when standing up from sitting.
• Check your feet regularly, since reduced sensation means an injury may not announce itself.

Where we are and how to start

Regenerve is located at 4477 Woodson Rd #104, St. Louis, MO 63134, minutes from St. Louis Lambert International Airport, and we see patients from across the St. Louis region, Missouri and Illinois. You can call or text (314) 886-5902, or email info@regenerve.com.

The free Nerve Damage Score is a five-question starting point that helps organize the driver question before your visit. Bring the result with you and we will build the evaluation around it.

Frequently asked questions

Can balance problems from neuropathy be caused by something other than diabetes?

Yes. Balance trouble can follow a nutritional driver, an autoimmune process, a toxic exposure, chemotherapy, or a structural problem, and more than one can be active at once. That is why we map the driver instead of assuming diabetes is the only mechanism. See how a “normal” B12 can still be a driver.

Does VNG balance testing treat my dizziness?

No. VNG (videonystagmography) is a diagnostic test of inner-ear balance function, not a treatment. It is useful when you have both numbness and dizziness, because it helps separate an inner-ear contribution from a nerve contribution. See what VNG balance testing measures.

Can class 4 photobiomodulation or cold laser fix my balance?

Neither is a balance treatment, and we do not present them as nerve regeneration or reversal. They are in-clinic modalities we may use alongside driver-based metabolic and nutritional care, and any balance benefit would follow from the overall plan rather than the device. See the treatments we offer.

I have burning feet at night as well as unsteadiness. Are those related?

They can be. Burning and reduced sensation are both outputs of the same nerve terrain, and small-fiber involvement can also affect autonomic control of blood pressure, which changes how steady you feel when you stand or turn. See small fiber neuropathy symptoms and testing.

I was told my neuropathy is idiopathic. Is there anything left to check?

Often yes. “Idiopathic” means no driver was identified, not that no driver exists, and mixed presentations are common. We re-open the driver map so the balance plan is built on a mechanism rather than a label. See the drivers that are commonly missed.

Sources

1. Centers for Disease Control and Prevention. Older Adult Falls Data. https://www.cdc.gov/falls/data-research/index.html (falls as the leading cause of injury, and more than 14 million adults ages 65 and older in the United States reporting a fall each year).
2. Journal of the American Medical Directors Association. Prevalence and Risk Factors for Falls in Older Adults With Diabetes: A Systematic Review and Meta-Analysis. 2025. https://www.jamda.com/article/S1525-8610(25)00529-8/fulltext (pooled falls prevalence of 29.5% across 32 studies and 23,666 older adults with diabetes).

The quickest separator is timing plus sensation. Plantar fasciitis is typically described as sharp pain under the heel that is worst with the first few steps out of bed and eases as you warm up, and it reproduces on pressure over the inner heel [2]. Nerve pain in the foot is more often burning, tingling or numbness, tends to involve the toes and forefoot, and frequently gets worse at night rather than better with movement.

Key takeaways

• Location: plantar fasciitis concentrates at the inner and under-surface of the heel, where the fascia attaches [2]. Nerve symptoms usually start in the toes and work upward.
• Timing: first-step morning pain that improves with movement suggests the fascia [2]. Burning that is worse at rest and at night suggests nerve.
• Sensation: tingling, numbness and electric or hot-coal sensations are nerve descriptions. The fascia does not produce them.
• Both can be present at once, which is why the presence of one does not close the question.
• In a 2013 survey of 75,000 US adults aged 18 and older, 0.85% (95% CI 0.77–0.92) reported diagnosed plantar fasciitis with pain in the past month [1].
• Numbness is a safety problem regardless of the cause, because an unfelt injury goes untreated.

What plantar fasciitis usually feels like

Plantar fasciitis is a mechanical problem at the tissue that runs along the sole and attaches at the heel. The description clinicians hear most is sharp pain that is worst on the first few steps in the morning or after sitting, then settles somewhat with activity [2].

On examination the pain is usually reproduced by pressing at the inner underside of the heel, at the point where the fascia inserts [2]. It is a focal, findable spot rather than a spreading sensation.

It is also common. In a 2013 internet panel survey of 75,000 US adults aged 18 and older, 0.85% reported diagnosed plantar fasciitis with pain in the previous month, and the reported figures were higher in women than men, higher in adults aged 45 to 64 than in younger adults, and higher at a BMI of 30 or above than below 25 [1].

What neuropathic foot pain usually feels like

Nerve pain reads differently. People describe burning, pins and needles, numbness, or a sense that the foot is padded or not fully theirs, and the sensations often do not sit over one findable point.

Distribution is the other clue. Because the longest nerve fibers fail first, symptoms typically begin in the toes and spread upward over time, often in both feet rather than one. This is what makes the distribution useful: mechanical pain does not migrate that way.

Why night is the tell

Mechanical pain generally responds to load: worse when you use it, better when you rest it. Nerve symptoms often do the opposite and become most noticeable when you are still, which is why burning feet at night is such a frequent complaint.

A side-by-side comparison

• Worst moment. Plantar fasciitis: first steps out of bed. Neuropathy: evening and night, at rest.
• Where. Plantar fasciitis: a focal spot at the inner heel. Neuropathy: toes and forefoot, spreading upward, usually both sides.
• Quality. Plantar fasciitis: sharp, mechanical, tied to load. Neuropathy: burning, electric, tingling, numb.
• Response to movement. Plantar fasciitis: eases as you warm up. Neuropathy: largely unchanged, or worse when you stop.
• Other findings. Plantar fasciitis: none beyond the foot. Neuropathy: often balance changes, reduced sensation, and symptoms in the hands later.

Use this to describe your symptoms accurately, not to reach a verdict. Mixed pictures are common, and the two can occur together.

Why it matters which one you are treating

Fascia care and nerve care do not overlap much. Months of stretching, orthotics and night splints aimed at a fascia problem will not address a nerve problem, and the delay costs more than the time.

Neuropathy is a category rather than a diagnosis, so identifying it is the beginning of the work, not the end. The next question is which driver is responsible: metabolic, nutritional, autoimmune, toxic or structural.

Numbness changes the urgency

Reduced protective sensation means blisters, burns and pressure injuries can go unnoticed until the skin has broken down. Check both feet daily, and treat an open area or a hot, swollen foot as a reason to be seen rather than to wait.

Sudden severe weakness, rapidly progressing numbness, or new loss of bladder or bowel control is an emergency and should go to emergency care, not to a clinic appointment.

How the evaluation works at Regenerve

Plantar fasciitis is diagnosed clinically, largely on history and on where the pain reproduces [2]. Nerve involvement needs measurement, and electrodiagnostic testing (EMG/NCS) is performed on site here.

Conduction studies characterize the larger fibers. When the story is burning and temperature change rather than numbness and weakness, the small fibers are the likely target and a different assessment is required, which is why we also use in-office small-fiber and vascular evaluation.

What treatment addresses, and what it does not promise

Regenerve offers class 4 photobiomodulation, class 3B cold laser, whole-body infrared, electrodiagnostic testing and metabolic and nutritional care, applied as components of a plan built around the identified driver. Orthobiologic injections such as PRP and BMAC are offered in selected situations.

We do not promise nerve regeneration, reversal, and we do not publish success percentages for our protocols.

Frequently asked questions

What is the single fastest way to tell them apart?

Ask what the first steps out of bed feel like. Sharp pain under the heel that is worst on the first few steps and eases as you move is the classic plantar fasciitis description, while burning, tingling or numbness that is worse at night and involves the toes points toward nerve involvement. See small fiber neuropathy symptoms and testing.

Can I have both at the same time?

Yes, and it is common enough that assuming one excludes the other is how people end up treating the wrong problem for months. Mechanical heel pain and nerve symptoms can coexist, and each needs its own answer. See peripheral neuropathy treatments for the feet.

Which test settles it?

No single test covers both. Plantar fasciitis is diagnosed clinically, largely on where the pain reproduces on examination, while nerve involvement is assessed with electrodiagnostic testing and, when the story is burning rather than weakness, with small-fiber assessment. See peripheral neuropathy of the feet symptoms.

My balance is off along with the foot pain. Is that related?

It might be a separate problem worth measuring rather than an extension of the foot pain. Videonystagmography is a diagnostic test of inner-ear balance function, used to work up unsteadiness; it is not a treatment for anything. See VNG balance testing.

Where can I be evaluated for this in the St. Louis area?

Addresses, hours and directions are listed on our Our St. Louis Neuropathy Clinic — Location & Directions page.

Start with the Nerve Damage Score

The entry point at Regenerve is the free five-question Nerve Damage Score. It takes a few minutes, and it tells us which driver to look at first so your visit starts with a plan instead of a guess.

Take the free Nerve Damage Score assessment, then bring the result to a physician-led visit at Regenerve, 4477 Woodson Rd #104, St. Louis, MO 63134, minutes from St. Louis Lambert International Airport. We see patients from the St. Louis region, Missouri and Illinois.

Sources

1. Nahin RL. “Prevalence and Pharmaceutical Treatment of Plantar Fasciitis in United States Adults.” The Journal of Pain, 2018;19(8). doi:10.1016/j.jpain.2018.03.003. https://pmc.ncbi.nlm.nih.gov/articles/PMC6066406/ — referenced for the 0.85% (95% CI 0.77–0.92) of 75,000 US adults aged 18 and older in the 2013 National Health and Wellness Survey who reported diagnosed plantar fasciitis with pain in the past month, and for the reported differences by sex, age band and BMI.
2. Buchanan BK, Sina RE, Kushner D. “Plantar Fasciitis.” StatPearls. StatPearls Publishing; updated January 7, 2024. https://www.ncbi.nlm.nih.gov/books/NBK431073/ — referenced for the first-step morning pain pattern, for pain at the inferior and medial heel reproduced on palpation at the plantar fascial insertion, and for plantar fasciitis being a clinical diagnosis.

The most useful question to ask an insurer is not “do you cover neuropathy testing.” It is “what documentation would support medical necessity for this specific test, for this specific suspected cause, in my case.” Coverage decisions turn on whether the record shows a clinical reason for the request, and neuropathy is a category rather than a diagnosis, so a chart that names only the category gives a reviewer very little to work with.

Key takeaways

• Ask about documentation and medical necessity, not about coverage in the abstract.
• Ask whether the request is being made for diagnosis or for monitoring, because plans often handle those differently.
• VNG is a diagnostic test of inner-ear balance function. It does not treat neuropathy, and it should not be described to a plan as though it does.
• Qutenza [Capsaicin 8% Patch] is FDA-approved in adults only for neuropathic pain from postherpetic neuralgia and from diabetic peripheral neuropathy of the feet [1]. Use for any other driver is off-label and must be documented as such.
• Orthobiologic injections such as PRP and BMAC are not FDA-approved for neuropathy. Plans generally do not cover them.
• We do not publish fees. They are discussed directly with the practice during planning.

Start with the purpose of the test, not the symptom

Most coverage conversations go sideways in the first sentence. The caller describes symptoms, the representative describes a policy, and nobody establishes what the test is meant to determine.

A clearer opening is to state the purpose: this study is being ordered to confirm or exclude a specific suspected cause of nerve symptoms. That framing is what a reviewer is looking for, and it is also what a good work-up produces anyway.

Questions worth asking word for word

• What documentation would support medical necessity for this test in my case?
• Does the answer change if the study is diagnostic rather than for monitoring?
• Is prior authorization required, and who submits it?
• If this is denied, what specifically would need to be added for an appeal?

Write the answers down with the date and the representative name. Appeals usually fail on missing documentation, not on disagreement about medicine.

Coverage questions change with the driver

A request tied to a suspected metabolic cause reads differently from one tied to a suspected nutritional, toxic, autoimmune or structural cause. That is not a billing trick, it is what an honest work-up looks like when the clinician has an actual hypothesis.

At Regenerve the sequence is the same regardless of insurer: identify the likely driver, choose the test that confirms or excludes it, then document why. The coverage conversation is easier because the clinical reasoning already exists.

Testing: what to separate before you call

Electrodiagnostic testing (EMG/NCS)

Electrodiagnostic testing is performed on site at Regenerve and measures conduction in the larger nerve fibers. If your symptoms are burning and temperature change rather than numbness and weakness, ask whether the order addresses large fibers, small fibers or both, because that distinction can determine which benefit category applies.

VNG balance testing

Videonystagmography is a diagnostic test of inner-ear balance function. It is used to work up unsteadiness and falls risk, and it does not treat neuropathy or anything else. When you call, ask how your plan handles vestibular diagnostics, which is a separate question from nerve testing. More detail is on our VNG balance testing page.

Treatments: where the coverage questions get specific

Qutenza (capsaicin 8% topical system)

Qutenza is FDA-approved in adults for neuropathic pain associated with postherpetic neuralgia and for neuropathic pain associated with diabetic peripheral neuropathy of the feet [1]. Applied to any other neuropathy driver, it is off-label, and the record should say so rather than blur the indication.

Two other label facts matter for planning. It is administered only by a physician or health care professional and is never dispensed for home use, and it is not repeated more frequently than every three months [1]. Our Qutenza page covers how the application visit works.

Orthobiologic injections (PRP and BMAC)

Plans generally do not cover them.

If this is under discussion, ask for that policy language in writing before scheduling anything, and expect the answer to be restrictive.

In-clinic light and infrared therapies

Class 4 photobiomodulation, class 3B cold laser and whole-body infrared are delivered in clinic as components of a plan rather than as one-time procedures. Ask which benefit category your plan assigns to office-based therapy and what documentation it expects per session type.

What we will and will not tell you about cost

We do not publish fees on this site. What a given patient owes depends on the plan, the benefits, and what the visit actually includes, and a posted number would be wrong for most people reading it.

What we will do is tell you directly, before scheduling, what a plan involves and what it costs in your situation. That conversation happens with the practice during planning.

Frequently asked questions

What should I ask my insurer before neuropathy testing?

Ask what documentation supports medical necessity for the specific test in your case, not whether neuropathy is covered in general. Then ask whether the answer differs for a diagnostic study versus repeat monitoring, because plans often treat those differently. Knowing which services are on the table first makes that call shorter, so review what we actually provide before you dial.

Why does my chart need to name a driver instead of just saying neuropathy?

Neuropathy is a category rather than a diagnosis, so a request that names only the category gives a reviewer nothing to evaluate against. When the record states the suspected driver and the test is tied to confirming or excluding it, the clinical reasoning is visible. See how the Regenerve protocol sequences testing.

Is coverage different for small-fiber evaluation than for EMG?

It can be. Electrodiagnostic testing measures the larger nerve fibers, so when your symptoms point at the small fibers a different assessment is needed and your plan may treat it under a different benefit category. Ask which fiber type the order addresses. See small fiber neuropathy symptoms and testing.

How do I find out what a visit will cost me?

We do not publish fees, because what applies to you depends on your plan, your benefits and what the visit actually includes. Fees are discussed directly with the practice during planning, before anything is scheduled. Reach us through the Regenerve contact page.

Start with the Nerve Damage Score

The entry point at Regenerve is the free five-question Nerve Damage Score. It takes a few minutes, and it tells us which driver to look at first so your visit starts with a plan instead of a guess.

Take the free Nerve Damage Score assessment, then bring the result to a physician-led visit at Regenerve, 4477 Woodson Rd #104, St. Louis, MO 63134, minutes from St. Louis Lambert International Airport. We see patients from the St. Louis region, Missouri and Illinois.

Sources

1. U.S. Food and Drug Administration. QUTENZA (capsaicin) topical system — Highlights of Prescribing Information, revised 07/2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022395s024lbl.pdf — referenced for the approved indications in adults (postherpetic neuralgia and diabetic peripheral neuropathy of the feet), for administration by a physician or health care professional only, and for repeat application not more frequently than every three months.

“Idiopathic” does not mean nothing can be found. It means no cause was identified by the evaluation that was performed. In a chart review of 284 patients referred to a neuropathy center carrying an idiopathic label, 93 (32.7%) remained idiopathic after thorough investigation, which also means roughly two thirds turned out to have an identifiable cause [1].

That is the whole argument for re-opening the question. Peripheral nerve disorders affect about 2.4% of the world population and about 8% of older populations [2], and the label attached at the first visit is frequently a description of how far the workup got.

Key points

• Idiopathic is a statement about the evaluation, not about the nerve.
• Neuropathy is a category, not a diagnosis. The work is identifying which driver is active: metabolic, nutritional, autoimmune, toxic or structural.
• Impaired glucose metabolism was the single most common cause found on re-evaluation of patients previously called idiopathic [1].
• Nerve conduction studies answer large-fiber questions. A normal study does not rule out small fiber involvement.
• Newer testing keeps moving the line: biallelic RFC1 repeat expansions were found in 2.3% of one large US idiopathic neuropathy cohort [3].

What the label actually describes

An idiopathic label usually reflects a specific gap: the wrong categories were emphasized, the timing of testing was off, or the pattern was never matched to the most informative test. None of those are statements about whether a cause exists.

It is also not a statement about severity. Neuropathy can keep progressing while the driver goes unmeasured, which is why a stalled workup is worth restarting when symptoms are changing.

How the workup maps a cause

Step one: identify the pattern and the fiber type

Peripheral neuropathy can involve small fibers, large fibers or both. Small fiber involvement tends to produce burning pain and temperature or sensory change; large fiber involvement more often shows up as numbness, unsteadiness and loss of position sense.

Getting that right early determines which tests are worth running, because the two patterns are answered by different tools.

Step two: connect the pattern to a driver category

A driver is a physiologic explanation for the malfunction. In practice the work is separating overlapping categories: metabolic (including impaired glucose metabolism short of diabetes), nutritional and digestive, toxic and environmental, and autoimmune, infectious or structural.

The published re-evaluation data support that emphasis. Among the 284 patients, impaired glucose metabolism accounted for 72 (25.3%), including 26 with diabetes and 46 with prediabetes; chronic inflammatory demyelinating polyneuropathy accounted for 57 (20%) and monoclonal gammopathy for 20 (7%), with toxic exposures, Sjögren disease, celiac disease, vitamin B12 deficiency, amyloidosis, vasculitis and hereditary causes making up the remainder [1]. Those categories are unpacked in the hidden drivers of peripheral neuropathy.

Step three: use testing to answer a question, not to assign a label

We perform electrodiagnostic testing (EMG/NCS) on site. It is the right instrument for large-fiber questions and for localizing a problem, and it is a poor instrument for confirming small fiber neuropathy, where studies can be normal.

When unsteadiness is part of the picture, videonystagmography (VNG) is used as a diagnostic test of inner-ear balance function. It separates a vestibular contribution from a nerve contribution. It is not a treatment.

Categories the workup actively looks for

Metabolic drivers

Glucose handling is the highest-yield place to look, and the published data reflect that. Documentation that stops at a normal fasting glucose can miss the impaired-glucose-metabolism group entirely.

Nutritional and digestive drivers

Vitamin B12 deficiency appeared among the identified causes in the re-evaluation series [1]. Absorption matters as much as intake, which is why digestion is part of the nutritional review rather than a separate topic.

Toxic and environmental drivers

Medications, alcohol, occupational exposures and, less obviously, supplements belong in the history. Excess vitamin B6 is one example of a supplement that can injure peripheral nerves rather than protect them.

Autoimmune and structural drivers

Immune-mediated neuropathies, including chronic inflammatory demyelinating polyneuropathy and neuropathies associated with monoclonal gammopathy, made up more than a quarter of the identified causes in that series [1]. Progression, weakness, asymmetry or systemic symptoms are reasons to widen the evaluation sooner.

Genetic drivers that were invisible until recently

Testing capability keeps changing what “idiopathic” covers. In a US cohort of 788 patients with idiopathic peripheral neuropathy, biallelic RFC1 AAGGG repeat expansions were found in 18 patients (2.3%), compared with 1 of 778 controls; the yield was highest, at 6.9%, in the pure sensory subgroup [3].

Turning findings into a plan

Once the dominant driver is identified, the plan follows the mechanism instead of cycling through options. Correcting a nutritional deficiency, addressing glucose handling and removing a toxic exposure are all driver-level work.

In-clinic therapies sit alongside that, not in place of it. We offer class 4 photobiomodulation, class 3B cold laser and whole-body infrared. Orthobiologic injections (PRP and BMAC) are offered in selected situations.

Qutenza (capsaicin 8% patch) is FDA-approved in adults for neuropathic pain from postherpetic neuralgia and from diabetic peripheral neuropathy of the feet; use for any other driver is off-label. It is applied in clinic by a clinician and repeated no more often than every three months.

None of this is a promise of nerve regeneration or reversal. It is a plan matched to what the workup found.

Frequently asked questions

Does “idiopathic” mean nothing more can be found?

No. It means the evaluation performed did not identify a cause. In a chart review of 284 patients referred to a neuropathy center with an idiopathic label, about two thirds were found to have an identifiable cause after thorough investigation. See small fiber neuropathy symptoms and testing.

Is an EMG and nerve conduction study enough on its own?

It is the right test for large-fiber involvement, but nerve conduction studies can be normal when the problem is confined to small fibers. When the symptom pattern points that way, the workup has to extend past EMG/NCS rather than stop at a normal result. We perform EMG/NCS on site; see our services and on-site testing.

Which causes are found most often once someone is re-evaluated?

In that same 284-patient review, impaired glucose metabolism was the most common cause, followed by chronic inflammatory demyelinating polyneuropathy and monoclonal gammopathy, with nutritional deficiencies including vitamin B12 among the rest. See functional B12 deficiency and neuropathy.

Can a gut or dietary problem explain nerve symptoms?

It can, both through malabsorption that drives nutritional deficiency and through immune-mediated mechanisms. Whether it applies to you is a hypothesis to test against your history and labs, not an assumption. See the gluten and neuropathy connection.

Is balance testing a treatment for neuropathy?

No. Videonystagmography (VNG) is a diagnostic test of inner-ear balance function. It helps separate an inner-ear contribution from a nerve contribution when someone is unsteady, and it does not treat anything. See VNG balance testing.

Next step

If you were told your neuropathy is idiopathic, the next step is a structured look at which driver is doing the most damage right now. Five questions start that map.

Sources

1. Farhad K, Traub R, Ruzhansky KM, Brannagan TH 3rd. Causes of neuropathy in patients referred as “idiopathic neuropathy.” Muscle & Nerve. 2016;53(6):856-861. doi:10.1002/mus.24969. https://pubmed.ncbi.nlm.nih.gov/26561790/
2. Hammi C, Yeung B. Neuropathy. StatPearls. Treasure Island (FL): StatPearls Publishing; last updated 15 October 2022. https://www.ncbi.nlm.nih.gov/books/NBK542220/
3. Tang Z, Ovunc SS, Iwase R, et al. Homozygous RFC1 AAGGG repeat expansions are common in idiopathic peripheral neuropathy. Annals of Neurology. 2026;100(1):95-108. doi:10.1002/ana.78226. https://pubmed.ncbi.nlm.nih.gov/41964406/

Yes, thyroid function can affect peripheral nerves, and it can do so before anyone uses the word neuropathy. In a study of 60 adults aged 20 to 50 with newly diagnosed hypothyroidism compared with 60 age-matched healthy controls, nerve conduction testing showed statistically significant increases in latency and decreases in conduction velocity and amplitude across motor and sensory nerves [1]. That does not mean your thyroid explains every symptom you have, but it does mean thyroid function belongs on the list of drivers you check.

Key takeaways

• Hypothyroidism has been associated with measurable nerve conduction changes in adults with newly diagnosed disease [1].
• Peripheral neuropathy is a category, not a diagnosis. The useful question is which driver is doing the damage: metabolic, nutritional, autoimmune, toxic or structural.
• Genetic evidence in people of European ancestry links hypothyroidism to higher odds of diabetic peripheral neuropathy, and did not show the same direction of effect for every neuropathy phenotype studied [2].
• Thyroid disease and metabolic disease frequently travel together, so finding one driver is not a reason to stop looking.
• Electrodiagnostic testing (EMG/NCS) is performed on site at Regenerve, so symptoms can be matched to measured nerve function rather than to a label.

Why hypothyroidism and nerve symptoms show up together

Peripheral nerves are metabolically demanding tissue. They depend on a steady oxygen supply through very small blood vessels and on stable cellular energy handling, and thyroid hormone influences both.

When thyroid hormone is low, that background environment shifts. The change is often subtle at first, which is why nerve testing can be abnormal before a person describes a clear pattern of numbness or burning.

None of this makes hypothyroidism the automatic explanation for foot symptoms. It makes thyroid status one of several things worth confirming before a work-up is called complete. If you want the wider list, read about the hidden drivers of peripheral neuropathy.

What the electrophysiology study actually found

The 2016 study in Annals of Medical and Health Sciences Research tested 60 adults aged 20 to 50 with recently diagnosed hypothyroidism against 60 age-matched healthy controls. In the motor nerves examined, the hypothyroid group showed significantly increased latencies and decreased conduction velocities [1].

The sensory nerves tested, median and sural, showed the same direction of change: longer latencies with reduced velocities and amplitudes [1]. The authors concluded that nerve involvement can develop at an early stage of hypothyroidism.

Two limits are worth stating plainly. This was a single study in adults aged 20 to 50, and abnormal conduction numbers are not the same thing as disabling symptoms.

Hypothyroidism and diabetic peripheral neuropathy: what the genetic data suggests

A 2024 Mendelian randomization study in Frontiers in Endocrinology examined eight nerve conditions using genetic data from people of European ancestry. It reported that genetically predicted hypothyroidism was associated with increased odds of diabetic peripheral neuropathy, with an odds ratio of 1.22 [2].

The same analysis did not point the same way for every phenotype. For polyneuropathies the estimate ran in the protective direction, which is a reminder that neuropathy subtypes do not behave as one disease [2].

Read this as a signal about vulnerability, not as proof that treating a thyroid lab will resolve nerve pain. It supports checking thyroid status carefully when diabetes and nerve symptoms are both present, alongside the blood sugar work that drives diabetic nerve damage.

Neuropathy is a category, so the work is finding the driver

Treating “neuropathy” as though it were one disease is the most common way a work-up stalls. The categories below are what we sort symptoms into before choosing testing.

Driver categories we evaluate

• Metabolic, including diabetes, prediabetes and thyroid disease.
• Nutritional, including B12 status and malabsorption after surgery.
• Autoimmune and inflammatory, when the pattern suggests an immune process targeting nerve.
• Toxic, including medication effects, alcohol and heavy metal exposure.
• Structural, including nerve entrapment and spine-related contributions.

More than one of these is often active at once. That is the practical reason we map before we treat.

How we test when thyroid disease and nerve symptoms overlap

Testing exists to separate three different problems: slowed conduction in the large nerve fibers, injury to the small fibers, and a nerve environment that is short on oxygen or under metabolic strain. Each one points somewhere different.

Electrodiagnostic testing (EMG/NCS) on site

Electrodiagnostic testing measures how well the larger nerves conduct and whether the pattern fits a length-dependent neuropathy, an entrapment or something else. At Regenerve this is performed on site rather than referred out.

Small-fiber and vascular assessment

Burning, temperature changes and pain out of proportion to the examination often involve the small fibers, which standard conduction studies do not capture. We use in-office assessments that look at small-fiber and vascular function so the plan is built on measurement.

What care looks like when the driver is metabolic or endocrine

Thyroid replacement is managed by the clinician prescribing it. Our work sits alongside that, and it is aimed at the environment around the nerve rather than at masking the signal.

In-clinic modalities we offer

Regenerve offers class 4 photobiomodulation, class 3B cold laser and whole-body infrared as components of a plan, applied in clinic under clinician direction. They are used to support the tissue environment while the identified driver is addressed, not as stand-alone answers.

What we do not claim

We do not promise nerve regeneration, reversal, and we do not publish success percentages for our protocols. What we can commit to is measuring before treating and telling you what the measurements show.

Frequently asked questions

Can hypothyroidism cause peripheral neuropathy?

Low thyroid function has been linked to measurable changes in nerve conduction. In a study of 60 adults aged 20 to 50 with newly diagnosed hypothyroidism and 60 age-matched healthy controls, motor and sensory nerves showed longer latencies and slower conduction velocities than in controls. That is a reason to test rather than assume, because more than one driver is often present. See peripheral neuropathy of the feet symptoms.

I have hypothyroidism and burning feet at night. What testing should I ask about?

Burning that is worse at night often points toward the small nerve fibers, which standard nerve conduction testing does not measure well. A useful evaluation separates large-fiber conduction from small-fiber and autonomic function, and checks for nutritional and toxic contributors at the same time. See small fiber neuropathy symptoms and testing.

Does thyroid disease change how diabetic neuropathy is managed?

It can change what gets looked at. A 2024 Mendelian randomization study in people of European ancestry reported that genetically predicted hypothyroidism was associated with higher odds of diabetic peripheral neuropathy, so thyroid status is worth confirming when both conditions are in play. The metabolic work does not change. See diabetic peripheral neuropathy treatment in St. Louis.

If my thyroid labs are treated and my feet still burn, what then?

That is common, and it usually means thyroid function was one contributor rather than the only one. The next step is to look for nutritional, toxic, autoimmune and structural drivers instead of repeating the same lab. See functional B12 deficiency and neuropathy.

Start with the Nerve Damage Score

The entry point at Regenerve is the free five-question Nerve Damage Score. It takes a few minutes, and it tells us which driver to look at first so your visit starts with a plan instead of a guess.

Take the free Nerve Damage Score assessment, then bring the result to a physician-led visit at Regenerve, 4477 Woodson Rd #104, St. Louis, MO 63134, minutes from St. Louis Lambert International Airport. We see patients from the St. Louis region, Missouri and Illinois.

Sources

1. Gupta N, Arora M, Sharma R, Arora KS. “Peripheral and Central Nervous System Involvement in Recently Diagnosed Cases of Hypothyroidism: An Electrophysiological Study.” Annals of Medical and Health Sciences Research, 2016;6(5). https://pmc.ncbi.nlm.nih.gov/articles/PMC5414436/ — referenced for the nerve conduction findings in 60 adults aged 20 to 50 with newly diagnosed hypothyroidism versus 60 age-matched healthy controls.
2. Frontiers in Endocrinology. “Causal relationship between hypothyroidism and peripheral neuropathy: a Mendelian randomization study of European ancestry.” 2024. doi:10.3389/fendo.2024.1436823. https://pmc.ncbi.nlm.nih.gov/articles/PMC11631618/ — referenced for the odds ratio of 1.22 for diabetic peripheral neuropathy in people of European ancestry and for the differing direction of effect across neuropathy phenotypes.

Peripheral neuropathy disrupts sleep because the pain it produces tends to get worse at night, and because broken sleep then makes the pain harder to tolerate. In diabetic peripheral neuropathy, the pain has been characterized as superficial, deep-seated, or severe, unremitting pain with exacerbation at night [1]. What helps is treating both halves of that loop: identify and address the driver behind the nerve injury, and stop the nights from feeding the next day’s symptoms.

The loop is not a metaphor. Neuropathic pain and sleep disturbance exacerbate each other, and there is evidence that sleep disruption may contribute to the progression from acute to chronic neuropathic pain [2].

Key takeaways

• Night-time worsening is a recognized feature of neuropathic pain, not a sign that you are imagining it.
• Sleep loss and pain reinforce each other, so a plan that addresses only one of them tends to stall.
• Neuropathy is a category, not a diagnosis, so the first move is identifying which driver is active.
• Burning, tingling, and numbness can each disturb sleep in different ways and point to different fiber involvement.
• Electrodiagnostic testing clarifies nerve involvement and pattern; it does not measure sleep.
• No treatment offered here reverses nerve damage, and none is promoted with an outcome percentage.

Why night-time feels worse

Symptoms do not clock out at bedtime. Many people notice that burning, electric sensations, tingling, and aching build through the evening, so that going to bed means lying still with an alarm that will not switch off.

Peripheral neuropathy commonly produces numbness, tingling, aching, and burning, along with hyperalgesia and allodynia [1]. When skin and nerves are sensitized, ordinary background sensations register as heat or pain, and lying still removes the distraction that daytime movement provides.

What the sleep-pain loop does

Sleep disturbance here is not only a consequence. Pain interferes with falling and staying asleep, and the resulting sleep disruption feeds back into the pain problem rather than resolving alongside it [2].

That is why bedtime routine advice alone rarely settles a neuropathic night. The mechanism producing the symptom has to be addressed as well.

Patterns that show up at bedtime

Night-time complaints tend to cluster. Some people describe a flare as they settle; others sleep for a few hours and are then woken by burning or by discomfort they cannot position away.

• Burning: hot-coal sensations and skin irritation that intensify once you stop moving.
• Reduced sensation: loss of protective sensation makes a comfortable position harder to find and raises awareness of pressure.
• Tingling and electric pain: abnormal firing that keeps you from settling even when medication takes the edge off.

Many people also describe a length-dependent pattern that starts in the toes and moves upward over time. That pattern points toward systemic drivers rather than a local foot problem.

Why the driver matters more than the label

Peripheral neuropathy encompasses a broad range of clinical pathologies [1], which means the night alarm can be driven by different mechanisms in different people. Metabolic stress, nutritional insufficiency, toxic exposure, autoimmune or infectious processes, and structural compression are all on the list.

If you have been told it is neuropathy without any account of the mechanism, you are left with volume control rather than a plan. The evaluation at Regenerve starts by identifying which driver is doing the most damage now.

Metabolic drivers and the glycation pathway

Glycation and advanced glycation end-products are part of how metabolic stress injures nerves, and that pathway can be relevant even when routine lab values look acceptable. Symptoms, labs, and metabolic pattern are read together rather than one marker at a time.

Nutritional and immune drivers

Gluten-related nerve injury can keep nerves sensitized in some patients whose standard celiac testing is negative. B12-related patterns are similar: a serum level inside the reference range does not always reflect functional status at the tissue level.

Small-fiber patterns

Small fiber involvement is especially disruptive at night, because it produces burning and hot sensations that feel skin-deep and are hardest to ignore when you are lying still. For the symptom language and how it is tested, see small fiber neuropathy symptoms and testing.

What testing does and does not tell you

Electrodiagnostic testing, meaning EMG and nerve conduction studies, is performed on site at Regenerve. It helps confirm nerve involvement and pattern, particularly large-fiber involvement, and it is most useful when there is weakness or when the distribution suggests a specific nerve or root.

It does not measure sleep, and it does not capture small-fiber involvement well. VNG is also performed on site, but it is a diagnostic test of inner-ear balance function and is not a treatment for neuropathy or for sleep.

What is used in clinic, and what it is for

Regenerve uses class 4 photobiomodulation, class 3B cold laser, and whole-body infrared alongside metabolic and nutritional care, guided by physician evaluation. These are aimed at the environment around the nerve, and they are used as part of a plan rather than as a package sold on their own.

Two other options carry conditions worth stating plainly. Qutenza, the capsaicin 8% patch, is FDA-approved in adults only for neuropathic pain associated with postherpetic neuralgia and with diabetic peripheral neuropathy of the feet; use for any other driver is off-label. It is applied in clinic by a clinician, never dispensed for home use, and repeated no more often than every three months [3].

Orthobiologic injections, meaning platelet-rich plasma and bone marrow aspirate concentrate, are offered here.

What none of this claims

Nerve tissue recovers slowly when it recovers at all, and nothing on this list is offered as a way to regenerate, reverse, or eliminate nerve damage. For how the pieces are sequenced, see the Regenerve protocol for peripheral neuropathy.

Practical steps discussed with patients

Alongside the medical plan, a few habits make the nights measurable rather than mysterious.

• Map the nights: note when burning and awakenings spike, and what positions, bedding, footwear, and evening activities change them.
• Bring the list: medications, supplements, alcohol, and exposures, since several of them are drivers in their own right.
• Protect the feet during the day: reduced sensation means daytime injury can surface as night-time symptoms.
• Raise sleep explicitly: if the nights are the worst part, say so, because it changes what gets prioritized.

Frequently asked questions

Why does neuropathy get worse at night?

Night-time exacerbation is a described feature of the neuropathic pain in diabetic peripheral neuropathy, and lying still removes the daytime input that competes with the symptom. Broken sleep then makes the following night harder rather than easier. For what actually helps in feet-first neuropathy, see peripheral neuropathy treatments for the feet.

Will treating my blood sugar fix the night-time burning?

It can help if metabolic stress is the dominant driver, but neuropathy is rarely explained by blood sugar alone and more than one driver can be active at once. That is why the evaluation looks at the whole picture rather than one number. For how metabolic injury reaches the nerve, see how glycation damages nerves.

My nerve pain started after shingles. Is that the same problem?

The mechanism is different, and so is the treatment path; postherpetic nerve pain has its own pattern and its own approved options. It is worth naming specifically rather than folding into a general neuropathy plan. For that pattern, see postherpetic neuralgia and shingles nerve pain.

Can in-clinic light or infrared therapy fix my sleep?

They are used to support the environment around the nerve, not as a sleep treatment, and they are not offered with any promise of nerve regeneration or reversal. Sleep tends to improve when the underlying driver is addressed and night-time symptoms settle. For what is available and how it is used, see the services offered at Regenerve.

Take the next step

If neuropathy is taking your nights, the first move is identifying the driver rather than adding another bedtime remedy. Start with the free five-question Nerve Damage Score. Regenerve is at 4477 Woodson Rd #104, St. Louis, MO 63134, minutes from St. Louis Lambert International Airport, serving the St. Louis region, Missouri and Illinois. Call or text (314) 886-5902, or email info@regenerve.com.

Sources

1. Bodman MA, Dreyer MA, Varacallo MA. “Diabetic Peripheral Neuropathy.” StatPearls. StatPearls Publishing; last updated February 25, 2024. https://www.ncbi.nlm.nih.gov/books/NBK442009/ (referenced for: neuropathic pain in diabetic peripheral neuropathy characterized as superficial, deep-seated, or severe, unremitting pain with exacerbation at night; symptom components including numbness, tingling, burning, hyperalgesia and allodynia; peripheral neuropathy encompasses a broad range of clinical pathologies).
2. Ho A, Drew VJ, Kim T. “What Links Sleep and Neuropathic Pain? A Literature Review on the Neural Circuits for Sleep and Pain Control.” Nature and Science of Sleep. 2025;17:813–838. doi:10.2147/NSS.S509013. https://pmc.ncbi.nlm.nih.gov/articles/PMC12065536/ (referenced for: neuropathic pain significantly disrupts sleep, creating a feedback loop in which pain and sleep disturbance exacerbate each other; evidence that sleep disruption may contribute to progression from acute to chronic neuropathic pain).
3. Averitas Pharma Inc. “QUTENZA (capsaicin) 8% topical system — prescribing information.” U.S. National Library of Medicine, DailyMed; label revised July 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ffbbcb0-ad93-4f15-bb38-5da76a71c735 (referenced for: indicated in adults for neuropathic pain associated with postherpetic neuralgia and for neuropathic pain associated with diabetic peripheral neuropathy of the feet; only physicians or health care professionals are to administer it; may be repeated not more frequently than every three months).